| Similar Articles |
|---|
 |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?   |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
May 2, 2011
Tim Beyers |
Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment. |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
July 30, 2010
Anand Chokkavelu |
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
October 14, 2010
Matt Koppenheffer |
Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume. |
The Motley Fool
November 22, 2011
Brian Orelli |
This Spec Pharma Hopes Convenience Trumps All Spectrum Pharmaceuticals' Zevalin no longer requires a bioscan. |
The Motley Fool
June 15, 2011
Brian Orelli |
Which Path Will Spectrum Pharmaceuticals Take? Spectrum Pharmaceuticals asked its shareholders to increase the number of authorized shares from 100 million to 175 million. Two days later, the company announced the repurchase of $25 million in shares. Confused? |
The Motley Fool
May 18, 2009
Brian Orelli |
Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price. |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
The Motley Fool
December 28, 2011
Brian Stoffel |
2011: The Year This Biotech Was Told to Share Procurement of smallpox vaccine has its ups and downs for SIGA Technologies. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
October 19, 2010
Travis Hoium |
Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri. |
The Motley Fool
December 11, 2007
Brian Orelli |
Medicare Whacks Oncology Drugs Bad news for some pharmaceutical companies as Medicare announces it is reducing the reimbursement rate for two lymphoma drugs. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
July 13, 2011
Sean Williams |
Shareholders Should Fire These 3 CEOs Is it time for these CEOs to step aside in the name of progress?: Antonio Perez of Kodak... Stephan Elop of Nokia... James Bianco of Cell Therapeutics... |
The Motley Fool
May 28, 2009
Robert Steyer |
Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena. |
BusinessWeek
November 10, 2003
Gene G. Marcial |
Ron Perelman Gives Siga A Boost Ronald Perelman is getting into biowarfare defense. Through his investment vehicle MacAndrews & Forbes, Perelman will invest $10 million in Siga Technologies, a tiny biotech that is developing oral drugs to prevent and treat diseases, including smallpox and anthrax. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them? |
